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ABSTRACT 
Background: Aromatase inhibitors improve disease-free survival compared with 
tamoxifen in postmenopausal women with hormone-receptor-positive breast cancer. The 
Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial compared exemestane 
monotherapy versus sequential therapy of tamoxifen followed by exemestane. The trial failed 
to show a significant difference between treatment arms. A robust translational program was 
established to investigate predictive biomarkers. 
Methods: A TMA was retrospectively constructed using a subset of patient tissue 
from the TEAM trial (n=4631/9766). Immunohistochemistry was performed for biomarkers, 
classed into three groups: MAPK pathway, NF-kappa B pathway, and ER phosphorylation. 
Expression was analysed for association with relapse-free survival (RFS) at 2.5 and 10 years 
and treatment regimen. 
Results: On univariate analysis, ER167 (HR 0.71 95% CI 0.59-0.85, p<0.001), IKKα 
(HR 0.74 95% CI 0.60-0.92, p=0.005), Raf-1338 (HR 0.64 95% CI 0.52-0.80, p<0.001), and 
p44/42 MAPK202/204 (HR 0.77 95% CI 0.64-0.92, p=0.004) were significantly associated with 
improved RFS at 10 years in patients receiving sequential therapy. Associations were 
strengthened when IKKα, Raf-1338 and ER167 were combined into a cumulative prognostic 
score (HR 0.64 95% CI 0.52-0.77, p<0.001). Patients with an all negative IKKα, Raf-1338 and 
ER167 score, favoured exemestane monotherapy (OR 0.56 95% CI 0.35-0.90). On 
multivariate analysis, the IKKα, Raf-1338 and ER167 score (p=0.001) was an independent 
prognostic factor for RFS at 10 years in patients receiving sequential therapy.  
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Conclusions: The IKKα, Raf-1338 and ER167 score is an independent predictive 
biomarker for lower recurrence on sequential therapy. Negative expression may further offer 
predictive value for exemestane monotherapy. 
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INTRODUCTION 
Treatment of breast cancer has evolved and tamoxifen is no longer the only adjuvant 
endocrine therapy available for postmenopausal women with estrogen receptor-positive (ER-
positive) [1]. Third generation aromatase inhibitors (AIs, anastrozole, exemestane and 
letrozole) which induce suppression of circulating estrogens increase disease free survival in 
postmenopausal hormone receptor-positive breast cancer. Treatment with AIs for 5 years 
improved disease-free survival compared with tamoxifen for 5 years [2, 3]. In the Intergroup 
Exemestane Study (IES), patients who switched to exemestane after 2–3 years of tamoxifen 
had significantly improved disease-free survival and overall survival compared to those 
remaining on tamoxifen [4]. Therefore AIs alone or in sequence with tamoxifen are now 
recommended as adjuvant therapy for postmenopausal breast cancer [5].  
Although currently there are established recurrence score such as Oncotype DX, 
Pam50 and the combined endocrine score [7-9], there are no biomarkers available to predict 
which patients will gain maximum benefit from each treatment strategy. NICE guidelines 
suggest that decisions should be based on discussions between the patient and oncologist, 
focussing on benefits and risks of each option, risk of recurrence and previous tamoxifen use 
[5]. Clearly biomarkers are required to aid clinician decision-making. The Tamoxifen and 
Exemestane Adjuvant Multinational (TEAM) trial compared exemestane monotherapy versus 
sequential therapy of tamoxifen followed by exemestane for a total of five years [10], 
providing an ideal cohort to retrospectively investigate biomarkers that predict patients most 
likely to benefit from either exemestane monotherapy or tamoxifen followed by exemestane. 
The TEAM trial did not show a specific benefit of one therapeutic regimen over the other, 
both after 5 and 10 years [10]. 
The current study investigated potential predictive biomarkers for endocrine therapy, 
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classed into three groups; MAPK pathway [11], NF-kappaB pathway [12], and 
phosphorylation of ER [13, 14] that have been previously reported as prognostic in 
postmenopausal hormone receptor-positive (HRec-positive) breast cancer.  
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PATIENTS AND METHODS 
Patients and study design 
The TEAM trial is a multinational, randomized, open-label, phase III trial in 
postmenopausal women with HRec-positive early breast cancer [10]. Women randomly 
received either exemestane (25mg) once daily for five years or tamoxifen (20mg) once daily 
for 2.5 years followed by exemestane for a total of five years. The study complied with the 
Declaration of Helsinki, individual ethics committee guidelines, and the International 
Conference of Harmonization and Good Clinical Practice Guidelines. All patients provided 
informed consent. 
From the 9766 patients from the TEAM trial, only five of the nine eligible TEAM 
countries (n=6210) agreed to provided tumour samples. 4781 patients had available tissue 
from surgical resections for tissue microarray (TMA) construction with linked 
clinicopathological data [15]. Of these 4631 patient samples were eligible for biomarker 
staining (figure 1). 86 patients were ER-negative, and 101 had cores missing for all stains and 
were therefore excluded leaving 4444 eligible patients for analysis. 
Immunohistochemistry 
Immunohistochemical expression of IKKα, p65536, N-Ras, Raf-1338, p44/42 
MAPK202/204, ER118, and ER167 was conducted on a TMA using the Benchmark XT (Ventana 
Medical Systems, Roche, USA) automated staining platform [15]. Stained TMA sections 
were scanned using a Hamamatsu NanoZoomer at x20 magnification and visualized on 
Slidepath Digital Image Hub (Leica Biosystems). If cores were missing or contained less than 
10% tumour tissue they were excluded from analysis (figure 1). Assessment of cytoplasmic 
IKKα expression was performed by a single examiner (LB) blinded to clinical data at x20 
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magnification (total magnification x400) using the weighted histoscore and 10% double 
scored by JE. The interclass coefficient (ICC) was 0.95. All other proteins were assessed 
using an automated computer algorithm of the weighted histoscore for nuclear expression, 
except N-Ras and Raf-1338 were cytoplasmic expression was assessed (Leica Biosystems). 
10% of tumours were manually scored by a single examiner (JE) blinded to the clinical data. 
The ICC for each biomarker was ER118 0.79, ER167 0.99, p65536 0.98, N-Ras 0.96, Raf-1338 
0.92, and p44/42 MAPK202/204 0.99.   
Outcomes 
The co-primary outcomes were relapse-free survival at 2.5 years (RFS; defined as 
time to earliest documentation of disease relapse or death due to breast cancer) and RFS at 10 
years. Secondary outcomes included biomarker associations with clinicopathological factors 
and treatment regimen. 
Statistical Analysis 
The prospectively powered outcome analysis for this study compared high expression 
(approximately 50%) and low expression (approximately 50%). By using a two-sided α=0.05 
analysis and assuming a hazard ratio (HR) of 1.2 and a low expression prevalence of 50%, a 
sample size of >1000 patients gave >90% power to detect a treatment-biomarker interaction. 
Therefore the 4646 eligible samples from this trial population would be adequate to identify 
treatment-biomarker interactions, with at least 90% power.  
Histograms were assessed for each protein and IKKα, ER167, Raf-1338 and p44/42 
MAPK202/204 histograms determined that negative and positive expression was the appropriate 
threshold. p65536, N-Ras, and ER118 were analysed using ROC analysis in a discovery cohort 
and validated using the current cohort, the following thresholds were determined for each 
protein: 25 for p65536, 100 for N-Ras, and 110 for ER118. SPSS (version 22) was used for 
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statistical analysis unless otherwise stated. Pearson’s χ2 test assessed associations between 
biomarkers, treatments, and clinicopathological features. Odds ratios compared biomarker 
associations with treatment regimens and were displayed as Forrest Plots with each 
biomarker as a separate study (RevMan 5.3). Kaplan-Meier and log-rank analysis compared 
RFS at both time points. HRs and CIs were calculated from univariate cox regression survival 
analysis. Multivariate cox regression survival analysis using a backward conditional 
elimination model and a significance threshold of p<0.01 was performed to identify 
independent prognostic biomarkers. The study conformed to the REMARK guidelines [16] 
and significance was set as p<0.01.  
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RESULTS 
Of the 9766 patients from the TEAM trial treated for HRec-positive early breast 
cancer, 4444 patients were included in this study (figure 1). Patient characteristics are shown 
in table 1. In brief, 100.0% were ER-positive, 68.3% PR-positive, 39.1% HER2-positive, and 
67.7% 60 years or older at surgery. 51.4% had grade II disease and 30.8% had grade III/IV 
disease. 57.6% were node positive and 8.9% had lymphovascular invasion. 2240 patients 
received exemestane monotherapy (50.4%) and 2204 patients received tamoxifen followed 
by exemestane therapy (49.6%). The median follow-up of survivors was 8.8 years (range 1.0-
13.9 years) with 1054 recurrences and 1161 deaths. When compared to the full TEAM trial, 
the characteristics of the patients were similar. However, the patients in the present study 
appeared to have higher grade, larger tumors and more nodal involvement. Nevertheless, the 
present cohort was a fair representation of the full TEAM trial.  
Univariate analysis of biomarker associations with relapse-free survival (RFS) at 2.5 
and 10 years are shown in table 2. ER118 phosphorylation was not associated with RFS at 
either time point. However, ER167 phosphorylation significantly associated with improved 
RFS at both 2.5 years (HR 0.73 95% CI 0.59-0.92, p=0.007) and 10 years (HR 0.82 95% CI 
0.71-0.94, p=0.004). For the NF-kappaB pathway, p65536 phosphorylation did not associate 
with RFS at either time point. However, positive IKKα expression significantly associated 
with improved RFS at 10 years (HR 0.80 95% CI 0.69-0.93, p=0.003). For the MAPK 
pathway, N-Ras did not associate with RFS at either time point. However, phosphorylation of 
Raf-1338 (HR 0.62 95% CI 0.48-0.81, p<0.001) and p44/42 MAPK202/204 (HR 0.70 95% CI 
0.56-0.88, p=0.002) strongly associated with improved RFS at 2.5 years. Both Raf-1338 (HR 
0.69 95% CI 0.59-0.80, p<0.001) and p44/42 MAPK202/204 (HR 0.76 95% CI 0.66-0.86, 
p<0.001) associations with improved RFS were strengthened at 10 years.  
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A cumulative prognostic score of the NF-kappa B and MAPK pathways was 
examined (IKKα and Raf-1338). Patients with positive IKKα expression and phosphorylation 
of Raf-1338 were classified as both-positive, patients with positive IKKα expression or Raf-
1338 phosphorylation as one-positive and patients with negative IKKα and Raf-1338 expression 
as both-negative. A both-positive IKKα and Raf-1338 score strengthened the association with 
improved RFS at 10 years (HR 0.78 95% CI 0.71-0.87, p<0.001) and 2.5 years (HR 0.77 95% 
CI 0.65-0.91, p=0.005). ER167 phosphorylation was added to the cumulative prognostic score. 
Patients with negative IKKα, Raf-1338 and ER167 were defined as all-negative, patients with 
positive expression of one or two from IKKα, Raf-1338 or ER167 as one/two-positive and 
patients with positive IKKα, Raf-1338 and ER167 as all-positive. Patients with an all-positive 
IKKα, Raf-1338 and ER167 score strengthened associations with improved RFS at 10 years 
(HR 0.73 95% CI 0.64-0.85, p<0.001). 
Univariate analysis was performed for treatment by biomarker interaction and its 
associations with RFS at 2.5 and 10 years as shown in table 3. Patients receiving tamoxifen 
followed by exemestane therapy had a significant improvement in RFS at 10 years with 
phosphorylation of ER167 (HR 0.71 95% CI 0.59-0.84, p<0.001). This was not observed in 
patients receiving exemestane monotherapy (HR 0.96 95% CI 0.79-1.16, p=0.66). Similarly, 
patients receiving tamoxifen followed by exemestane therapy had a significant improvement 
in RFS at 10 years with positive IKKα expression (HR 0.74 95% CI 0.60-0.92, p=0.005, 
figure 2A). This was not observed in patients receiving exemestane monotherapy (HR 0.86 
95% CI 0.69-1.07, p=0.17, figure 2A). Furthermore, patients receiving tamoxifen followed 
by exemestane therapy had improved RFS at 2.5 years when Raf-1338 (HR 0.58 95% CI 0.41-
0.83, p=0.003) or p44/42 MAPK202/202 (HR 0.66 95% CI 0.49-0.89, p=0.006) is 
phosphorylated, which was not observed in patients receiving exemestane monotherapy (Raf-
1338: HR 0.68 95% CI 0.47-0.98, p=0.03 or p44/42 MAPK202/204: HR 0.77 95% CI 0.56-1.06, 
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p=0.11). However, this different pattern between treatment regimens for Raf-1338 and p44/42 
MAPK202/204 was lost by 10 years (table 3). No biomarker by treatment associations (figure 3) 
were observed at 10 years for either Raf-1338 (OR 0.97 95% CI 0.83-1.12) or p44/42 
MAPK202/204 (OR 0.96 95% CI 0.83-1.11). 
For the IKKα and Raf-1338 score, patients with a both-positive score receiving 
tamoxifen followed by exemestane therapy also showed a significant improvement in RFS at 
10 years (HR 0.73 95% CI 0.63-0.84, p<0.001, figure 2B). However, when assessing 
biomarker by treatment interactions, patients with negative IKKα expression receiving 
tamoxifen followed by exemestane therapy had shorter RFS than patients receiving 
exemestane monotherapy, although this did not reach significance (HR 1.24 95% CI 0.1.02-
1.51, p=0.03, figure 4A). Furthermore, patients with a both-negative IKKα and Raf-1338 score 
do significantly worse on tamoxifen followed by exemestane compared to exemestane 
monotherapy (HR 1.35 95% CI 1.08-1.68, p=0.009, figure 4B). These results were then 
confirmed with forest plots for biomarker by treatment interactions (figure 3), with both 
negative IKKα expression (OR 0.79 95% CI 0.63-0.99) and a both-negative IKKα and Raf-
1338 score (OR 0.72 95% CI 0.55-0.93) favouring exemestane monotherapy. 
To assess how interactions between all three pathways associate with treatment 
regimen, the IKKα, Raf-1338 and ER167 score was assessed (table 3). Patients receiving 
tamoxifen followed by exemestane therapy with an all-positive IKKα, Raf-1338 and ER167 
score had significantly improved survival at 10 years (HR 0.64 95% CI 0.52-0.77, p<0.001, 
figure 2C). This was not observed for exemestane monotherapy (HR 0.70 95% CI 0.51-0.95, 
p=0.08, figure 2C). When assessing biomarker by treatment associations, patients with an all-
negative IKKα, Raf-1338 and ER167 score favoured exemestane monotherapy (OR 0.56 95% 
CI 0.35-0.90, figure 3). 
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Since IKKα, Raf-1338, p44/42 MAPK202/204, and ER167 associated with RFS and 
patient treatments, associations with common clinicopathological factors were assessed 
(Table S1). ER167 phosphorylation significantly associated with lower grade (p=0.001), 
whereas IKKα significantly associated with lower nodal status (p<0.001) and Ki67 index 
(p=0.008). Raf-1338 significantly associated with lower grade (p<0.001), lower nodal status 
(p<0.001), smaller size (p<0.001), increased PR status (p<0.001), and decreased Ki67 index 
(p=0.004). Whereas p44/42 MAPK202/204 significantly associated with lower age (p=0.001), 
lower grade (p<0.001), lower nodal status (p<0.001), and decreased lymphovascular invasion 
(p<0.001). 
IKKα, Raf-1338, p44/42 MAPK202/204, and ER167 were then taken forward into 
multivariate analysis along with age, grade, nodal status, size, PR status and Ki67 index 
(table 4). In the full cohort, multivariate survival analysis for RFS at 2.5 years (n=2827) 
showed age (p<0.001), nodal status (p<0.001), size (p=0.002), and Ki67 index (p<0.001) 
were independent prognostic factors. Whereas multivariate survival analysis for RFS at 10 
years (n=1963) demonstrated that age (p<0.001), size (p<0.001), HER2 status (p=0.001), and 
Ki67 index (p=0.006) were independent prognostic factors. Patients were then split by 
treatment regimen and multivariate analysis performed for each cohort (table 4). For patients 
receiving exemestane monotherapy, RFS at 2.5 years (n=1429) showed age (p=0.004), nodal 
status (p=0.001), size (p=0.008), and Ki67 index (p=0.001) were independently prognostic. 
Similarly, RFS at 10 years (n=980) showed age (p<0.001), size (p<0.001), and PR status 
(p=0.003) were independent prognostic factors. Whereas for patients receiving tamoxifen 
followed by exemestane therapy, RFS at 2.5 years (n=1398) showed age (p<0.001), nodal 
status (p=0.008), and Ki67 index (p=0.001) were independently prognostic. However, RFS at 
10 years (n=983) showed age (p=0.001), size (p=0.001), ER167 phosphorylation (p=0.002), 
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the IKKα and Raf-1338 score (p=0.008), and the IKKα, Raf-1338 and ER167 score (p=0.001) 
were independent prognostic factors. 
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DISCUSSION 
The current study demonstrated that an all-positive IKKα, Raf-1338 and ER167 score is 
an independent predictor of response to sequential therapy of tamoxifen followed by 
exemestane. Furthermore, an all-negative IKKα, Raf-1338 and ER167 score is predictive for 
response to exemestane monotherapy. Utilizing IKKα, Raf-1338 and ER167 could ensure the 
most effective endocrine therapy regimen is administered to patients. 
Bennett et. al. reported that high IKKα expression was associated with shorter RFS in 
ER-positive tamoxifen-treated patients [12]. In contrast, the present study reports that IKKα 
expression is associated with improved RFS in ER-positive patients receiving tamoxifen 
followed by exemestane. This discordance may be explained by differences in the thresholds 
employed; Bennett et al. employed the median whereas the present study used positive and 
negative, making direct comparisons difficult. Nevertheless, the data suggests that the 
addition of exemestane changes the prognostic power of IKKα. During long-term tamoxifen 
treatment (5 years), blockade of ER lead to higher free estrogen levels promoting the 
formation of an ER/IKKα complex to enhance transcriptional activity, which results in 
reduced RFS after 2 years as observed by Bennett et al. [17]. However, if exemestane is 
administered following short-term tamoxifen treatment (2.5 years), estrogen levels fall and 
the ER/IKKα complex is released to phosphorylate ER in a ligand-independent manner 
resulting in improved RFS as observed in the current study [17]. This is not observed in the 
exemestane monotherapy patients, as the initial formation of the ER/IKKα complex is 
required to improve RFS. 
Of interest, McGlynn et al. reported that high Raf-1338 was associated with shorter 
RFS on tamoxifen [11]. However, in the present study, patients that received tamoxifen for 
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2.5 years showed an increase in RFS, which was also observed for both treatments at 10 
years. Again, this discordance may be due to differences in the thresholds used for the two 
studies; McGlynn et al. used the upper quartile whereas the present study assessed negative 
or positive, making direct comparisons difficult. Therefore it would appear that depending on 
the threshold employed slightly different results may be obtained. Of note, these studies are 
retrospective and may be subject to selection biases. However, other studies observed that 
when estrogen production is ablated, p44/42 MAPK phosphorylates ER167 to induce 
transcription of alternative ER-dependent genes [18]. When tamoxifen is administered long-
term, the partial agonist activity of tamoxifen causes activation of ER, which in turn activates 
Raf-1 causing increased tumor growth as observed by McGlynn et al. However, when 
estrogen production is ablated by exemestane alone or following short-term tamoxifen 
treatment, ER-independent phosphorylation of Raf-1338 can promote p44/42 MAPK to 
phosphorylate ER167 resulting in up-regulation of alternative gene transcription, conveying 
good prognosis to the patients as observed in the present study [19].   
The cumulative prognostic score demonstrated that patients with both-positive IKKα 
and Raf-1338 expression had a better prognosis on tamoxifen followed by exemestane therapy 
compared to patients with negative expression of one of the biomarkers, suggesting it could 
be used as a predictive biomarker for patients receiving sequential therapy. Previous studies 
have demonstrated that IKKα can phosphorylate p44/42 MAPK suggesting IKK alpha may 
work with Raf-1 to enhance ER167 phosphorylation [20]. To assess this ER167 phosphorylation 
was added to the cumulative prognostic score. Associations with improved RFS were 
enhanced in patients receiving tamoxifen followed by exemestane therapy, suggesting IKKα 
and Raf-1 independently phosphorylate ER167. This was confirmed in exemestane 
monotherapy patients as no improvement in RFS was observed suggesting the addition of the 
primed ER/IKK alpha complex enhances the beneficial effects of ER167. This data suggest 
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that an all-positive IKKα, Raf-1338 and ER167 score could be utilized as a predictive 
biomarker for lower recurrence in patients receiving tamoxifen followed by exemestane 
therapy.   
Conversely, patients with an all-negative IKKα, Raf-1338 and ER167 score favored 
exemestane monotherapy with significantly improved RFS. This suggests that when IKKα 
and Raf-1 are not present, the build-up of free estrogens during tamoxifen treatment promote 
tumour progression by competing for ER and exemestane is unable to stop this detrimental 
effect without IKKα and Raf-1. However, in the exemestane monotherapy patients, estrogens 
never activate ER, inhibiting tumour recurrence. These results suggest that an all-negative 
IKKα, Raf-1338 and ER167 score might be utilized to select patients for exemestane 
monotherapy.  
The present study also assesses HER2 status and uses 10-year follow-up, which was 
not available when the trial was originally reported. The main limitation of this study is its 
retrospective nature and that of the 9766 patients included in the TEAM trial, only 4444 
patients had tissue available for use in this study. Furthermore, of the 4444 patient in the 
present cohort, only 2827 were included in the multivariate analysis due to missing data. 
However, even with these limitations the IKKα, Raf-1338 and ER167 score was demonstrated 
to predict recurrence in postmenopausal breast cancer patients treated with endocrine therapy. 
Patients with an all-positive score should be treated with sequential therapy of tamoxifen 
followed by exemestane, whereas patients with an all-negative score should be treated with 
exemestane monotherapy. As the results describe predictive biomarkers for response to 
different endocrine therapy regimens and not prognostic biomarkers of general recurrence, it 
is not clear how the present work may be incorporated into existing recurrence models.   
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In conclusion, although validation is warranted in other translational studies of 
comparative clinical trial patients, utilizing the IKKα, Raf-1338 and ER167 score could ensure 
the most effective endocrine therapy regimen is administered to patients most likely to gain 
maximum benefit. Furthermore, this cumulative score is readily translatable to the clinical 
scenario as it utilizes techniques already in daily use and is scored as negative or positive 
which is easily automated within this setting. These observations may only apply to a 
minority of patients, however applying the correct treatment at the correct time is a key goal 
in personalised medicine and is likely to improve the outcome of patients with breast cancer.   
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FIGURE LEGEND 
Figure 1. Flow diagram showing criteria for exclusion of patients from study.  
Figure 2. IKKα, Raf-1338 and ER167 score as a prognostic biomarker for recurrence in 
patients receiving tamoxifen followed by exemestane therapy. (A) Kaplan Meier showing 
RFS at 10 years for IKKα in patients receiving either exemestane monotherapy or tamoxifen 
followed by exemestane therapy. (B) Kaplan Meier showing RFS at 10 years for the IKKα 
and Raf-1338 score in patients receiving either exemestane monotherapy or tamoxifen 
followed by exemestane therapy (C) Kaplan Meier showing RFS at 10 years for the IKKα, 
Raf-1338 and ER167 score in patients receiving either exemestane monotherapy or tamoxifen 
followed by exemestane therapy. 
Figure 3. Biomarker associations with treatment regimen. Forest plot for RFS at 10 years, 
showing whether a biomarker favours exemestane monotherapy or tamoxifen followed by 
exemestane therapy, in postmenopausal early breast cancer patients. 
Figure 4. Both negative IKKα and Raf-1338 score as a predictive biomarker for 
exemestane monotherapy. (A) Kaplan Meier showing RFS at 10 years for treatment 
regimen in patients with either negative or positive expression of IKKα. (B) Kaplan Meier 
showing RFS at 10 years for treatment regimen in patients with either a both negative or both 
positive IKKα and Raf-1338 score.  
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*RFS = relapse-free survival; †HR = Hazard Ratio; ‡CI = Confidence interval; §-- = data not available 
 
 
Table 1. Baseline characteristics of patients  
 TEAM study 
(n=9766) 
Pathology substudy 
(n=6120) 
Biomarker substudy 
(n=4444) 
 Patient No (%) Patient No (%) Patient No (%) Univariate Analysis 
    RFS* 2.5 
events 
RFS 10 
events 
Relapse-free survival @ 2.5yrs Relapse-free survival @ 10yrs 
      HR† (95% CI‡) p value HR (95% CI) p value 
Age  
<50 
50-59 
60-69 
>70 
 
331 (3.2) 
3017 (30.9) 
3731 (38.4) 
2687 (27.5) 
 
211 (3.4) 
1874 (30.6) 
2373 (38.8) 
1662 (27.2) 
 
115 (2.6) 
1322 (29.7) 
1703 (38.3) 
1304 (29.4) 
 
7 
88 
129 
146 
 
22 
240 
357 
435 
1.31 (1.16-1.49) <0.001 1.42 (1.32-1.53) <0.001 
Grade  
1 
2 
3-4 
Unknown 
 
1677 (17.2) 
4795 (49.1) 
2438 (25.0) 
856 (8.7) 
 
616 (10.1) 
3166 (51.8) 
1835 (30.0) 
503 (8.1) 
 
520 (11.7) 
2284 (51.4) 
1369 (30.8) 
271 (6.1) 
 
33 
168 
150 
19 
 
91 
529 
371 
63 
1.27 (1.11-1.45) 0.001 1.15 (1.07-1.24) <0.001 
Nodal Status  
absent 
present 
unknown 
 
5113 (52.4) 
4585 (46.9)  
68 (0.7) 
 
2604 (42.5) 
3494 (57.1) 
22 (0.4) 
 
1884 (42.4) 
2560 (57.6) 
0 (0) 
 
117 
253 
- 
 
353 
701 
- 
1.62 (1.30-2.02) <0.001 1.52 (1.34-1.73) <0.001 
Size  
<20mm 
>20mm 
Unknown 
 
5697 (58.3) 
4047 (41.4) 
22 (0.3) 
 
3028 (49.4) 
3027 (49.4) 
65 (1.2) 
 
2139 (48.1) 
2172 (48.9) 
133 (3.0) 
 
124 
237 
- 
 
363 
662 
- 
1.95 (1.56-2.42) <0.001 1.97 (1.74-2.24) <0.001 
PR status  
absent 
present 
not performed 
 
1724 (17.7) 
7301 (74.8) 
741 (7.5) 
 
1070 (17.5) 
4378 (71.5) 
672 (11.0) 
 
826 (18.6) 
3034 (68.3) 
584 (13.1) 
 
101 
224 
45 
 
261 
658 
135 
1.14 (0.99-1.31) <0.001 1.12 (1.03-1.21) <0.001 
HER2 Status 
absent 
present 
not performed 
 
-§ 
- 
- 
 
2796 (45.7) 
1908 (31.2) 
1416 (23.1) 
 
1776 (39.7) 
1738 (39.1) 
940 (21.2) 
 
134 
159 
- 
 
377 
469 
- 
1.21 (0.96-1.52) 0.11 1.22 (1.06-1.40) 0.005 
Ki67 status  
low (<15) 
high (>15) 
unknown 
 
- 
- 
- 
 
2308 (37.7) 
1064 (17.4) 
2748 (44.9) 
 
2277 (51.2) 
1027 (23.1) 
1140 (25.7) 
 
156 
127 
- 
 
489 
305 
- 
1.87 (1.48-2.36) <0.001 1.48 (1.29-1.71) <0.001 
Treatment  
exemestane 
tamoxifen then exemestane 
 
4898 (50.2) 
4868 (49.8) 
 
3075 (50.2) 
3045 (49.8) 
 
2240 (50.4) 
2204 (49.6) 
 
1169 
1201 
 
523 
531 
1.22 (1.00-1.50) 0.05 1.05 (0.93-1.18) 0.45 
Lymphovascular Invasion  
no 
yes 
unknown 
 
- 
- 
- 
 
3845 (62.8) 
403 (6.6) 
1872 (30.6) 
 
3727 (83.9) 
394 (8.9) 
323 (7.2) 
 
299 
40 
- 
 
881 
101 
- 
0.78 (0.56-1.08) 0.13 0.90 (0.73-1.10) 0.31 
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*RFS = relapse-free survival; †HR = Hazard Ratio; ‡CI = Confidence interval; §WHS – weighted histoscore 
 
Table 2. Univariate analysis of associations between biomarkers and RFS at 2.5 and 10 years in postmenopausal HRec-positive early 
breast cancer patients. 
 Number of 
Patients 
RFS* 2.5 
events 
RFS 10 
events 
Relapse-free survival @ 2.5yrs Relapse-free survival @ 10yrs 
    HR† (95% CI‡)   p value HR (95% CI)   p value 
phospho ER118 (n=4218) 
low expression (<110 WHS§ units) 
high expression (>110 WHS units) 
 
3157 
1061 
 
266 
86 
 
777 
218 
0.96 (0.75-1.22) 0.73 0.83 (0.71-0.96) 0.01 
phospho ER167 (n=4133) 
negative expression (0 WHS units) 
positive expression (>0 WHS units) 
 
1150 
2983 
 
115 
222 
 
304 
670 
0.73 (0.59-0.92) 0.007 0.82 (0.71-0.94) 0.004 
IKK alpha (n=3024) 
negative expression (0 WHS units) 
positive expression (>0 WHS units) 
 
1579 
1445 
 
144 
114 
 
400 
298 
0.86 (0.68-1.11) 
 
0.24 
 
 
0.80 (0.69-0.93) 
 
0.003 
 
 
phospho p65536 (n=4053) 
low expression (<25 WHS units) 
high expression (>25 WHS units) 
 
857 
3196 
 
70 
271 
 
219 
739 
1.03 (0.79-1.34) 
 
0.81 
 
 
0.89 (0.77-1.04) 
 
0.15 
 
 
N-Ras (n=4039) 
low expression (<100 WHS units) 
high expression (>100 WHS units) 
 
3952 
87 
 
337 
5 
 
929 
28 
0.66 (0.28-1.61) 
 
0.36 
 
 
1.36 (0.94-1.96) 
 
0.11 
 
 
Raf-1338 (n=4030) 
negative expression (0 WHS units) 
positive expression (>0 WHS units) 
 
2797 
1233 
 
266 
74 
 
728 
224 
0.62 (0.48-0.81) <0.001 0.69 (0.59-0.80) <0.001 
p44/42 MAPK202/204 (n=4055) 
negative expression (0 WHS units) 
positive expression (>0 WHS units) 
 
2249 
1806 
 
217 
125 
 
590 
369 
0.70 (0.56-0.88) 0.002 0.76 (0.66-0.86) <0.001 
IKK alpha and Raf-1338 (n=2980) 
both negative 
one positive 
both positive 
 
1154 
1158 
668 
 
115 
102 
37 
 
316 
254 
116 
0.77 (0.65-0.91) 0.005 0.78 (0.71-0.87) <0.001 
IKK alpha, Raf-1338 and ER167 (n=2904) 
all negative 
one or two positive 
all positive 
 
339 
2037 
528 
 
37 
178 
29 
 
104 
471 
93 
0.71 (0.56-0.89) 0.01 0.73 (0.64-0.85) <0.001 
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*RFS = relapse-free survival; †HR = Hazard Ratio; ‡CI = Confidence interval 
 
 
Table 3. Univariate analysis of associations between biomarkers, treatment regimen, and RFS at 2.5 and 10 years in postmenopausal 
HRec-positive early breast cancer patients  
 Exemestane Tamoxifen then exemestane 
 Number 
of 
Patients 
RFS* 
2.5 
events 
RFS 10 
events 
Relapse-free survival @ 2.5yrs Relapse-free survival @ 10yrs Number 
of 
Patients 
RFS 
2.5 
events 
RFS 10 
events 
Relapse-free survival @ 2.5yrs Relapse-free survival @ 10yrs 
    HR† (95% CI‡)   p value HR (95% CI)   p value    HR (95% CI)   p value HR (95% CI)   p value 
ER118  
low expression  
high expression  
 
1587 
550 
 
112 
47 
 
380 
115 
1.22 (0.87-1.71) 0.26 0.87 (0.71-1.07) 0.19  
1570 
511 
 
154 
39 
 
397 
103 
0.77 (0.54-1.09) 0.14 0.78 (0.63-0.97) 0.03 
ER167  
negative expression  
positive expression  
 
594 
1491 
 
55 
96 
 
141 
342 
0.68 (0.49-0.95) 0.02 0.96 (0.79-1.16) 0.66  
556 
1492 
 
60 
126 
 
163 
342 
0.77 (0.57-1.05) 0.10 0.71 (0.59-0.85) <0.001 
IKK alpha  
negative expression  
positive expression  
 
791 
744 
 
65 
49 
 
183 
150 
0.80 (0.55-1.16) 0.23 0.86 (0.69-1.07) 0.17  
788 
701 
 
79 
65 
 
217 
148 
0.93 (0.67-1.29) 0.66 0.74 (0.60-0.92) 0.005 
p65536  
low expression  
high expression  
 
422 
1623 
 
28 
127 
 
112 
362 
1.19  (0.79-1.79) 0.41 0.83 (0.67-1.02) 0.08  
453 
1573 
 
42 
144 
 
107 
377 
0.93 (0.69-1.32) 0.69 0.97 (0.78-1.20) 0.76 
N-Ras  
low expression  
high expression  
 
1991 
48 
 
154 
1 
 
459 
14 
0.26 (0.04-1.87) 0.15 1.22 (0.72-2.08) 0.46  
1961 
39 
 
183 
4 
 
470 
14 
1.10 (0.41-2.96) 0.85 1.55 (0.91-2.64) 0.10 
Raf-1338  
negative expression  
positive expression  
 
1390 
641 
 
117 
37 
 
352 
120 
0.68 (0.47-0.98) 0.04 0.74 (0.60-0.91) 0.004  
1407 
592 
 
149 
37 
 
376 
104 
0.58 (0.41-0.83) 0.003 0.64 (0.52-0.80) <0.001 
p44/42 MAPK202/204  
negative expression  
positive expression 
 
1103 
942 
 
93 
62 
 
286 
188 
0.77 (0.56-1.06) 0.11 0.75 (0.62-0.90) 0.002  
1146 
864 
 
124 
63 
 
304 
181 
0.66 (0.49-0.89) 0.006 0.77 (0.64-0.92) 0.004 
IKK alpha and Raf-1338 
both negative 
one positive 
both positive 
 
570 
590 
346 
 
48 
46 
18 
 
137 
132 
58 
0.81 (0.63-1.04) 0.18 0.85 (0.73-0.98) 0.05  
584 
568 
322 
 
67 
56 
19 
 
179 
122 
58 
0.74 (0.59-0.93) 0.03 0.73 (0.63-0.84) <0.001 
IKK alpha, Raf-1338 and ER167 
all negative 
one or two positive 
all positive 
 
167 
1027 
271 
 
15 
80 
13 
 
41 
229 
49 
0.73 (0.51-1.03) 0.17 0.57 (0.70-1.04) 0.27  
172 
1010 
257 
 
22 
98 
16 
 
63 
242 
44 
0.70 (0.51-0.95) 0.08 0.64 (0.52-0.77) <0.001 
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*HR = Hazard Ratio; †CI = Confidence interval, ‡-- = not included in analysis 
 
 
Table 4. Multivariate analysis of associations between biomarkers, clinicopathological characteristics, and RFS at 2.5 and 10 years in 
postmenopausal HRec-positive early breast cancer patients by treatment 
 All Patients (n=4444) Exemestane Only (n=2240) Tamoxifen followed by Exemestane (n=2204) 
 Relapse-free survival @ 2.5yrs 
(n=2827) 
Relapse-free survival @ 10yrs 
(n=1963) 
Relapse-free survival @ 2.5yrs 
(n=1429) 
Relapse-free survival @ 10yrs 
(n=980) 
Relapse-free survival @ 2.5yrs 
(n=1398) 
Relapse-free survival @ 10yrs 
(n=983) 
 HR* (95% CI†) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value 
Age  
<50/50-59/60-69/>70 
1.43 (1.23-1.67) <0.001 1.34 (1.20-1.50) <0.001 1.41 (1.11-1.78) 0.004 1.38 (1.18-1.62) <0.001 1.48 (1.20-1.83) <0.001 1.30 (1.11-1.52) 0.001 
Grade  
1/2/3/4 
1.24 (1.04-1.48) 0.02 1.14 (1.01-1.29) 0.04 1.32 (1.01-1.75) 0.04 1.10 (0.92-1.31) 0.28 1.12 (0.90-1.40) 0.32 1.16 (0.97-1.37) 0.10 
Nodal Status  
absent/present 
1.78 (1.34-2.36) <0.001 1.39 (1.08-1.79) 0.01 2.02 (1.31-3.11) 0.001 1.36 (0.93-1.98) 0.12 1.65 (1.14-2.38) 0.008 1.26 (0.87-1.83) 0.22 
Size  
<20mm/>20mm 
1.54 (1.18-2.02) 0.002 1.70 (1.42-2.06) <0.001 1.75 (1.16-2.64) 0.008 1.82 (1.37-2.40) <0.001 1.44 (1.01-2.06) 0.04 1.61 (1.23-2.11) 0.001 
PR status  
absent/present 
1.13 (0.94-1.36) 0.20 1.17 (1.00-1.38) 0.05 1.33 (1.02-1.72) 0.04 1.46 (1.16-1.85) 0.001 0.96 (0.74-1.25) 0.78 0.98 (0.79-1.22) 0.86 
HER2 status 
absent/present 
-‡ - 1.39 (1.15-1.62) 0.001 - - 1.35 (1.04-1.79) 0.02 - - 1.40 (1.06-1.85) 0.02 
Ki67 status  
Low/High 
1.87 (1.44-2.42) <0.001 1.33 (1.09-1.62) 0.006 1.96 (1.32-2.92) 0.001 1.37 (1.04-1.79) 0.03 1.78 (1.27-2.50) 0.001 1.32 (1.00-1.73) 0.05 
phospho ER167  
negative/positive  
0.88 (0.67-1.16) 0.35 0.79 (0.65-0.96) 0.02 0.78 (0.52-1.17) 0.23 0.99 (0.74-1.32) 0.92 1.00 (0.69-1.45) 0.99 0.65 (0.50-0.85) 0.002 
IKK alpha  
absent/present  
- - 0.91 (0.76-1.14) 0.34 - - 1.09 (0.83-1.42) 0.55 - - 0.81 (0.63-1.06) 0.11 
Raf-1338 (n=4030) 
negative/positive 
0.71 (0.52-0.97) 0.03 0.85 (0.65-1.12) 0.26 0.72 (0.46-1.14) 0.16 1.01 (0.68-1.49) 0.98 0.81 (0.51-1.29) 0.37 0.66 (0.50-0.98) 0.04 
p44/42 MAPK202/204  
negative/positive 
0.92 (0.70-1.20) 0.53 0.92 (0.76-1.13) 0.45 1.21 (0.81-1.81) 0.36 0.90 (0.70-1.19) 0.46 0.70 (0.49-1.01) 0.06 0.98 (0.74-1.30) 0.90 
IKK alpha and Raf-1338  
both negative/one 
positive/both positive 
0.82 (0.68-0.99) 0.38 0.89 (0.77-1.04) 0.13 0.79 (0.60-1.05) 0.11 1.03 (0.83-1.27) 0.80 0.81 (0.63-1.05) 0.11 0.76 (0.62-0.93) 0.008 
IKK alpha, Raf-1338 and ER167  
all negative/one or two 
positive/all positive 
- - 0.81 (0.68-0.96) 0.01 - - 0.97 (0.76-1.24) 0.83 - - 0.67 (0.54-0.85) 0.001 
